Driving Rare Kidney Diseases Market Growth in 2025: The Role of Government Catalysts Fueling Rare Kidney Disease Market Surge

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Rare Kidney Diseases Market Size Growth Forecast: What to Expect by 2025?
The market for rare kidney diseases has witnessed robust growth in the preceding years. It is expected to rise from $2.76 billion in 2024 to $3.03 billion in 2025, registering a compound annual growth rate (CAGR) of 9.6%. This growth during the historic period can be attributed to factors such as enhanced disease identification, designation of orphan drugs, patient advocacy and awareness expansion, along with worldwide research collaborations.

How Will the Rare Kidney Diseases Market Size Evolve and Grow by 2029?
Anticipations are high for robust expansion in the rare kidney diseases market over the coming years. The market is projected to reach "$4.41 billion by 2029, with a compound annual growth rate (CAGR) of 9.8%. The growth drivers forecasted for this period can be traced to the advent of gene therapies, escalating investments in research for rare diseases, partnerships among key players, and worldwide efforts towards tackling rare diseases. The main trends to watch for in the upcoming period include a patient-focused strategy, the application of real-world evidence and data analysis methods, changes in regulations, the adoption of telemedicine and distance monitoring, and international health enterprises.

View the full report here:
https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

What Drivers Are Propelling the Growth of Rare Kidney Diseases Market Forward?
The expected growth of the rare kidney disease market is set to be accelerated by government initiatives and financial backing for kidney disorders. These initiatives and funds provided by the government serve as financial assistance for selected projects or concepts that enhance and contribute to public services and economic growth. These aids are used to amplify disease monitoring and improve the lives of individuals living with diverse kidney diseases by employing a thorough public health plan which cooperates with other public health institutions and national organizations. For example, the United States House Committee on Appropriations, which is a committee of the House of Representatives in the US, in July 2022, launched numerous investment programs to further kidney health. This encompassed $8.5 million funding for the Chronic Kidney Disease Program of the Centers for Disease Control and Prevention (CDC), intending to enhance activities for regular awareness, diagnosis, and treatment of kidney disease. In addition, a $1 million investment was made toward the National Living Donor Assistance Center for living donations, increasing the total to $8 million in consistent investment for research and innovation. As a result, the growth of the rare kidney disease market is being facilitated by government initiatives and financial support for kidney disorders.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11908&type=smp

What Long-Term Trends Will Define the Future of the Rare Kidney Diseases Market?
The focus on product innovation is a leading trend in the rare kidney disease market, with key market players investing in the development of new products to fortify their market position. To illustrate, STADA Arzneimittel AG, a German company specializing in generics, specialty pharma, and over-the-counter consumer healthcare products, in September 2022, unveiled Kinpeygo (budesonide). This medicine is the first to be authorized in the European Union for the treatment of a unique kidney condition known as immunoglobulin A nephropathy (IgAN). These modified-release capsules of budesonide are the only accepted treatment for primary IgAN, a rare, advancing autoimmune kidney disease with a substantial unmet medical need. Over 25%-30% of individuals with this condition eventually require dialysis or a kidney transplant due to terminal kidney failure.

What Are the Key Segments in the Rare Kidney Diseases Market?
The rare kidney diseases market covered in this report is segmented -

1) By Target Indication: IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy, Other Target Indications
2) By Type Of Molecule: Small Molecules, Biologics
3) By Route Of administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

Subsegments:
1) By IgA Nephropathy: Immunosuppressive Therapy, Supportive Care And Symptomatic Management
2) By Lupus Nephritis: Corticosteroids, Antimalarial Agents, Biologics
3) By Focal Segmental Glomerular Sclerosis (FSGS): Corticosteroids, Angiotensin Receptor Blockers (ARBs), Other Immunosuppressive Agents
4) By Membranous Nephropathy: Corticosteroids, Immunosuppressive Therapy, Monoclonal Antibodies
5) By C3 Glomerulopathy: Complement Inhibitors, Supportive Care, Immunosuppressive Therapies
6) By Other Target Indications: Alport Syndrome, Thin Basement Membrane Nephropathy, Other Rare Kidney Disorders

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=11908&type=smp

Who Are the Key Players Shaping the Rare Kidney Diseases Market's Competitive Landscape?
Major companies operating in the rare kidney diseases market include Merck & Co. Inc., Novartis AG, Sanofi S.A, AstraZeneca plc, Otsuka Pharmaceutical Co Ltd., Alexion Pharmaceuticals Inc., Horizon Therapeutics plc., Recordati S.p.A., Amicus Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics, FibroGen Inc., Aurinia Pharmaceuticals Inc., Calliditas Therapeutics AB, Apellis Pharmaceuticals Inc., Protalix Biotherapeutics Inc., ChemoCentryx Inc., Omeros Corporation, Celtaxsys Inc., Corbus Pharmaceuticals Holdings Inc., Chinook Therapeutics Inc., OxThera AB, Advicenne Pharma SA, Reata Pharmaceuticals Inc., Savara Inc.

What Geographic Markets Are Powering Growth in the Rare Kidney Diseases Market?
North America was the leading region in the rare kidney disease market in 2024. The regions covered in the rare kidney diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11908

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.